VILDAGLIPTIN
▸ Vildafast-M is Inhibits dipeptidyl peptidase-4 and prevents degradation of glucagon like peptide-1 in patients with type 2 diabetes mellitus
No accumulation of drug is seen following the administration of multiple doses because of short elimination life
▸Vildafast-M Does not possess adverse gastrointestinal events compliance and adherence to patients improves
METFORMIN
▸ First line therapy for patients with Type 2 Diabetes Mellitus
▸ Combination therapy reduces the pill burden and improves patient compliance